Gasdermin-E (Inversely correlated with estrogen receptor expression 1) (ICERE-1) (Non-syndromic hearing impairment protein 5) [Cleaved into: Gasdermin-E, N-terminal (GSDME-NT); Gasdermin-E, C-terminal (GSDME-CT)]
1_MFAKA 6_ TRNFL 11_ REVDA 16_ DGDLI 21_ AVSNL 26_ NDSDK 31_ LQLLS 36_ LVTKK 41_ KRFWC 46_ WQRPK 51_ YQFLS 56_ LTLGD 61_ VLIED 66_ QFPSP 71_ VVVES 76_ DFVKY 81_ EGKFA 86_ NHVSG 91_ TLETA 96_ LGKVK 101_ LNLGG 106_ SSRVE 111_ SQSSF 116_ GTLRK 121_ QEVDL 126_ QQLIR 131_ DSAER 136_ TINLR 141_ NPVLQ 146_ QVLEG 151_ RNEVL 156_ CVLTQ 161_ KITTM 166_ QKCVI 171_ SEHMQ 176_ VEEKC 181_ GGIVG 186_ IQTKT 191_ VQVSA 196_ TEDGN 201_ VTKDS 206_ NVVLE 211_ IPAAT 216_ TIAYG 221_ VIELY 226_ VKLDG 231_ QFEFC 236_ LLRGK 241_ QGGFE 246_ NKKRI 251_ DSVYL 256_ DPLVF 261_ REFAF 266_ IDMPD 271_ AAHGI 276_ SSQDG 281_ PLSVL 286_ KQATL 291_ LLERN 296_ FHPFA 301_ ELPEP 306_ QQTAL 311_ SDIFQ 316_ AVLFD 321_ DELLM 326_ VLEPV 331_ CDDLV 336_ SGLSP 341_ TVAVL 346_ GELKP 351_ RQQQD 356_ LVAFL 361_ QLVGC 366_ SLQGG 371_ CPGPE 376_ DAGSK 381_ QLFMT 386_ AYFLV 391_ SALAE 396_ MPDSA 401_ AALLG 406_ TCCKL 411_ QIIPT 416_ LCHLL 421_ RALSD 426_ DGVSD 431_ LEDPT 436_ LTPLK 441_ DTERF 446_ GIVQR 451_ LFASA 456_ DISLE 461_ RLKSS 466_ VKAVI 471_ LKDSK 476_ VFPLL 481_ LCITL 486_ NGLCA 491_LGREH
1: Precursor of a pore-forming protein that converts non-inflammatory apoptosis to pyroptosis (PubMed:27281216, PubMed:28459430, PubMed:33852854, PubMed:35594856, PubMed:36607699). This form constitutes the precursor of the pore-forming protein: upon cleavage, the released N-terminal moiety (Gasdermin-E, N-terminal) binds to membranes and forms pores, triggering pyroptosis (PubMed:28459430)
2: Pore-forming protein produced by cleavage by CASP3 or granzyme B (GZMB), which converts non-inflammatory apoptosis to pyroptosis or promotes granzyme-mediated pyroptosis, respectively (PubMed:27281216, PubMed:28459430, PubMed:32188940, PubMed:33852854, PubMed:35594856). After cleavage, moves to the plasma membrane, homooligomerizes within the membrane and forms pores of 10-15 nanometers (nm) of inner diameter, allowing the release of mature interleukins (IL1B and IL16) and triggering pyroptosis (PubMed:28459430, PubMed:32188940, PubMed:33852854, PubMed:35594856). Binds to inner leaflet lipids, bisphosphorylated phosphatidylinositols, such as phosphatidylinositol (4,5)-bisphosphate (PubMed:28459430). Cleavage by CASP3 switches CASP3-mediated apoptosis induced by TNF or danger signals, such as chemotherapy drugs, to pyroptosis (PubMed:27281216, PubMed:28459430, PubMed:32188940). Mediates secondary necrosis downstream of the mitochondrial apoptotic pathway and CASP3 activation as well as in response to viral agents (PubMed:28045099). Exhibits bactericidal activity (PubMed:27281216). Cleavage by GZMB promotes tumor suppressor activity by triggering robust anti-tumor immunity (PubMed:21522185, PubMed:32188940). Suppresses tumors by mediating granzyme-mediated pyroptosis in target cells of natural killer (NK) cells: cleavage by granzyme B (GZMB), delivered to target cells from NK-cells, triggers pyroptosis of tumor cells and tumor suppression (PubMed:31953257, PubMed:32188940). May play a role in the p53/TP53-regulated cellular response to DNA damage (PubMed:16897187)
3: (Microbial infection) Pore-forming protein, which promotes maternal placental pyroptosis in response to Zika virus infection, contributing to adverse fetal outcomes